Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

Longboard Pharmaceuticals (LBPH) gained 14.4% on Jul 1 after it announced that the FDA has granted Breakthrough Therapy designation for its investigational drug, bexicaserin, to treat seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients aged two years or older. The FDA's Breakthrough Therapy designation is a process that speeds up the development and review of drugs for serious or life-threatening conditions. This designation is granted when early clinical evidence sugge ...